Cargando…
Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma
Diffuse gastric carcinoma (DGC) is characterized by poorly cohesive cells, highly invasive growth patterns, poor prognosis and resistance to the majority of available systemic therapeutic strategies. It has been previously reported that the Wnt/β-catenin signaling pathway serves a prominent role in...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527567/ https://www.ncbi.nlm.nih.gov/pubmed/34691249 http://dx.doi.org/10.3892/ol.2021.13083 |
_version_ | 1784586093566361600 |
---|---|
author | Sremac, Maja Paic, Frane Grubelic Ravic, Katja Serman, Ljiljana Pavicic Dujmovic, Aja Brcic, Iva Krznaric, Zeljko Nikuseva Martic, Tamara |
author_facet | Sremac, Maja Paic, Frane Grubelic Ravic, Katja Serman, Ljiljana Pavicic Dujmovic, Aja Brcic, Iva Krznaric, Zeljko Nikuseva Martic, Tamara |
author_sort | Sremac, Maja |
collection | PubMed |
description | Diffuse gastric carcinoma (DGC) is characterized by poorly cohesive cells, highly invasive growth patterns, poor prognosis and resistance to the majority of available systemic therapeutic strategies. It has been previously reported that the Wnt/β-catenin signaling pathway serves a prominent role in the tumorigenesis of gastric carcinoma. However, the mechanism underlying the dysregulation of this pathway in DGC has not been fully elucidated. Therefore, the present study aimed to investigate the expression profiles of Wnt antagonists, secreted frizzled-related protein 1 (SFRP1) and secreted frizzled-related protein 3 (SFRP3), and dishevelled protein family members, dishevelled segment polarity protein 2 (DVL2) and dishevelled segment polarity protein 3 (DVL3), in DGC tissues. The association between the expression levels of these factors and the clinicopathological parameters of the patients was determined. Protein and mRNA expression levels in 62 DGC tumor tissues and 62 normal gastric mucosal tissues obtained from patients with non-malignant disease were measured using immunohistochemical and reverse transcription-quantitative PCR (RT-qPCR) analysis. Significantly lower protein expression levels of SFRP1 (P<0.001) and SFRP3 (P<0.001), but significantly higher protein expression levels of DVL2 (P<0.001) and DVL3 (P<0.001) were observed in DGC tissues compared with in control tissues by immunohistochemistry. In addition, significantly lower expression levels of SFRP1 (P<0.05) and higher expression levels of DVL3 (P<0.05) were found in in DGC tissues compared with those in normal gastric mucosal tissues using RT-qPCR. According to correlation analysis between the SFRP1, SFRP3, DVL2 and DVL3 protein expression levels and the clinicopathological characteristics of patients with DGC, a statistically significant correlation was found between the SFRP3 volume density and T stage (r=0.304; P=0.017) and between the SFRP3 volume density and clinical stage (r=0.336; P=0.008). In conclusion, the findings of the present study suggested that the Wnt signaling pathway components SFRP1, SFRP3, DVL2 and DVL3 may be aberrantly expressed in DGC tissues, implicating their possible role in the development of this malignant disease. The present data also revealed a positive relationship between SFRP3 protein expression and the clinical and T stage of DGC. |
format | Online Article Text |
id | pubmed-8527567 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-85275672021-10-22 Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma Sremac, Maja Paic, Frane Grubelic Ravic, Katja Serman, Ljiljana Pavicic Dujmovic, Aja Brcic, Iva Krznaric, Zeljko Nikuseva Martic, Tamara Oncol Lett Articles Diffuse gastric carcinoma (DGC) is characterized by poorly cohesive cells, highly invasive growth patterns, poor prognosis and resistance to the majority of available systemic therapeutic strategies. It has been previously reported that the Wnt/β-catenin signaling pathway serves a prominent role in the tumorigenesis of gastric carcinoma. However, the mechanism underlying the dysregulation of this pathway in DGC has not been fully elucidated. Therefore, the present study aimed to investigate the expression profiles of Wnt antagonists, secreted frizzled-related protein 1 (SFRP1) and secreted frizzled-related protein 3 (SFRP3), and dishevelled protein family members, dishevelled segment polarity protein 2 (DVL2) and dishevelled segment polarity protein 3 (DVL3), in DGC tissues. The association between the expression levels of these factors and the clinicopathological parameters of the patients was determined. Protein and mRNA expression levels in 62 DGC tumor tissues and 62 normal gastric mucosal tissues obtained from patients with non-malignant disease were measured using immunohistochemical and reverse transcription-quantitative PCR (RT-qPCR) analysis. Significantly lower protein expression levels of SFRP1 (P<0.001) and SFRP3 (P<0.001), but significantly higher protein expression levels of DVL2 (P<0.001) and DVL3 (P<0.001) were observed in DGC tissues compared with in control tissues by immunohistochemistry. In addition, significantly lower expression levels of SFRP1 (P<0.05) and higher expression levels of DVL3 (P<0.05) were found in in DGC tissues compared with those in normal gastric mucosal tissues using RT-qPCR. According to correlation analysis between the SFRP1, SFRP3, DVL2 and DVL3 protein expression levels and the clinicopathological characteristics of patients with DGC, a statistically significant correlation was found between the SFRP3 volume density and T stage (r=0.304; P=0.017) and between the SFRP3 volume density and clinical stage (r=0.336; P=0.008). In conclusion, the findings of the present study suggested that the Wnt signaling pathway components SFRP1, SFRP3, DVL2 and DVL3 may be aberrantly expressed in DGC tissues, implicating their possible role in the development of this malignant disease. The present data also revealed a positive relationship between SFRP3 protein expression and the clinical and T stage of DGC. D.A. Spandidos 2021-12 2021-10-08 /pmc/articles/PMC8527567/ /pubmed/34691249 http://dx.doi.org/10.3892/ol.2021.13083 Text en Copyright: © Sremac et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Sremac, Maja Paic, Frane Grubelic Ravic, Katja Serman, Ljiljana Pavicic Dujmovic, Aja Brcic, Iva Krznaric, Zeljko Nikuseva Martic, Tamara Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma |
title | Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma |
title_full | Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma |
title_fullStr | Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma |
title_full_unstemmed | Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma |
title_short | Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma |
title_sort | aberrant expression of sfrp1, sfrp3, dvl2 and dvl3 wnt signaling pathway components in diffuse gastric carcinoma |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527567/ https://www.ncbi.nlm.nih.gov/pubmed/34691249 http://dx.doi.org/10.3892/ol.2021.13083 |
work_keys_str_mv | AT sremacmaja aberrantexpressionofsfrp1sfrp3dvl2anddvl3wntsignalingpathwaycomponentsindiffusegastriccarcinoma AT paicfrane aberrantexpressionofsfrp1sfrp3dvl2anddvl3wntsignalingpathwaycomponentsindiffusegastriccarcinoma AT grubelicravickatja aberrantexpressionofsfrp1sfrp3dvl2anddvl3wntsignalingpathwaycomponentsindiffusegastriccarcinoma AT sermanljiljana aberrantexpressionofsfrp1sfrp3dvl2anddvl3wntsignalingpathwaycomponentsindiffusegastriccarcinoma AT pavicicdujmovicaja aberrantexpressionofsfrp1sfrp3dvl2anddvl3wntsignalingpathwaycomponentsindiffusegastriccarcinoma AT brciciva aberrantexpressionofsfrp1sfrp3dvl2anddvl3wntsignalingpathwaycomponentsindiffusegastriccarcinoma AT krznariczeljko aberrantexpressionofsfrp1sfrp3dvl2anddvl3wntsignalingpathwaycomponentsindiffusegastriccarcinoma AT nikusevamartictamara aberrantexpressionofsfrp1sfrp3dvl2anddvl3wntsignalingpathwaycomponentsindiffusegastriccarcinoma |